Multiple sclerosis: pharmacogenomics and personalised drug treatment

被引：0
|
作者：
V. Annibali
G. Ristori
S. Cannoni
S. Romano
A. Visconti
A. Ghazaryan
L. Figà Talamanca
M. Salvetti
R. Mechelli
机构：
[1] Ospedale S. Andrea,Department of Neurology and Centro Neurologico Terapia Sperimentale (CENTERS)
[2] University of Rome “La Sapienza”,undefined
来源：
Neurological Sciences | 2006年 / 27卷
关键词：
Pharmacogenomics; Multiple sclerosis; Therapy; Microarrays;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Multiple sclerosis (MS) is a disorder of the central nervous system with an inflammatory and a neurodegenerative component. We do not yet have a definitive therapy for MS. Attempts to develop new treatments are long and costly and should be paralleled by studies aimed at increasing the therapeutic index of the existing treatments, interferon β and glatiramer acetate. Pharmacogenetics and pharmacogenomics may be of use in this respect though their application may not be straightforward, particularly in MS.
引用
收藏
页码：s347 / s349
相关论文
共 50 条
  • [1] Multiple sclerosis: pharmacogenomics and personalised drug treatment
    Annibali, V.
    Ristori, G.
    Cannoni, S.
    Romano, S.
    Visconti, A.
    Ghazaryan, A.
    Talamanca, L. Figa
    Salvetti, M.
    Mechelli, R.
    NEUROLOGICAL SCIENCES, 2006, 27 (Suppl 5) : S347 - S349
  • [2] Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy
    Tsareva, E. Yu.
    Kulakova, O. G.
    Makarycheva, O. Yu.
    Boyko, A. N.
    Shchur, S. G.
    Lashch, N. Yu.
    Popova, N. F.
    Gusev, E. I.
    Bashinskaya, V. V.
    Lvov, D. V.
    Favorov, A. V.
    Ochs, M. F.
    Favorova, O. O.
    MOLECULAR BIOLOGY, 2011, 45 (06) : 886 - 893
  • [3] The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis
    Kowalec, Kaarina
    Carleton, Bruce
    Tremlett, Helen
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2013, 2 (03) : 183 - 192
  • [4] United Europeans for development of pharmacogenomics in multiple sclerosis network
    Vandenbroeck, Koen
    Comabella, Manuel
    Tolosa, Eva
    Goertsches, Robert
    Brassat, David
    Hintzen, Rogier
    Infante-Duarte, Carmen
    Favorov, Alexander
    Escorza, Sergio
    Palacios, Ricardo
    Oksenberg, Jorge R.
    Villoslada, Pablo
    PHARMACOGENOMICS, 2009, 10 (05) : 885 - 894
  • [5] Current Developments in Pharmacogenomics of Multiple Sclerosis
    Rebecca J. Carlson
    J. Ronald Doucette
    Adil J. Nazarali
    Cellular and Molecular Neurobiology, 2014, 34 : 1081 - 1085
  • [6] IFN-β pharmacogenomics in multiple sclerosis
    Vandenbroeck, Koen
    Urcelay, Elena
    Comabella, Manuel
    PHARMACOGENOMICS, 2010, 11 (08) : 1137 - 1148
  • [7] Pharmacogenomics of Multiple Sclerosis: A Systematic Review
    Hocevar, Keli
    Ristic, Smiljana
    Peterlin, Borut
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [8] Current Developments in Pharmacogenomics of Multiple Sclerosis
    Carlson, Rebecca J.
    Doucette, J. Ronald
    Nazarali, Adil J.
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2014, 34 (08) : 1081 - 1085
  • [9] Immunomodulatory drug treatment in multiple sclerosis
    Aharoni, Rina
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (09) : 1423 - 1436
  • [10] Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach
    Vosslamber, Saskia
    van Baarsen, Lisa G. M.
    Verweij, Cornelis L.
    PHARMACOGENOMICS, 2009, 10 (01) : 97 - 108
12345